Continental Advisors LLC Cuts Stock Position in Bausch Health Companies Inc. (NYSE:BHC)

Continental Advisors LLC lowered its stake in Bausch Health Companies Inc. (NYSE:BHC) by 76.9% during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 23,000 shares of the company’s stock after selling 76,576 shares during the period. Continental Advisors LLC’s holdings in Bausch Health Companies were worth $730,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of the stock. Lombard Odier Asset Management USA Corp grew its stake in shares of Bausch Health Companies by 10.6% in the 1st quarter. Lombard Odier Asset Management USA Corp now owns 53,433 shares of the company’s stock worth $1,696,000 after buying an additional 5,133 shares during the last quarter. Voloridge Investment Management LLC purchased a new stake in Bausch Health Companies during the 1st quarter valued at $18,083,000. Amundi Asset Management US Inc. boosted its stake in Bausch Health Companies by 27.4% during the 1st quarter. Amundi Asset Management US Inc. now owns 88,399 shares of the company’s stock valued at $2,806,000 after purchasing an additional 19,008 shares during the last quarter. Odey Asset Management Group Ltd purchased a new stake in Bausch Health Companies during the 1st quarter valued at $86,000. Finally, Jackson Square Capital LLC purchased a new stake in Bausch Health Companies during the 1st quarter valued at $355,000. Institutional investors own 67.71% of the company’s stock.

Several analysts have commented on BHC shares. HC Wainwright reiterated a “buy” rating on shares of Bausch Health Companies in a research note on Thursday, July 8th. Royal Bank of Canada lowered their price target on Bausch Health Companies from $42.00 to $41.00 and set an “outperform” rating on the stock in a report on Wednesday, May 5th. Finally, Bank of America reissued an “underperform” rating and set a $27.00 price target on shares of Bausch Health Companies in a report on Tuesday, March 30th. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the company. Bausch Health Companies has an average rating of “Hold” and a consensus target price of $33.00.

Bausch Health Companies stock traded down $0.37 during trading on Thursday, reaching $28.66. The company had a trading volume of 32,004 shares, compared to its average volume of 1,531,409. Bausch Health Companies Inc. has a 52 week low of $14.86 and a 52 week high of $34.80. The business’s 50-day moving average is $30.13. The stock has a market capitalization of $10.27 billion, a price-to-earnings ratio of 6.84, a price-to-earnings-growth ratio of 0.52 and a beta of 1.70. The company has a debt-to-equity ratio of 39.55, a current ratio of 1.10 and a quick ratio of 0.88.

Bausch Health Companies (NYSE:BHC) last announced its earnings results on Monday, May 3rd. The company reported $1.04 EPS for the quarter, topping the Zacks’ consensus estimate of $0.94 by $0.10. Bausch Health Companies had a positive return on equity of 352.44% and a negative net margin of 12.66%. The company had revenue of $2.03 billion for the quarter, compared to analysts’ expectations of $2.08 billion. During the same period last year, the firm earned $0.88 EPS. Bausch Health Companies’s revenue for the quarter was up .7% compared to the same quarter last year. On average, sell-side analysts forecast that Bausch Health Companies Inc. will post 4.25 EPS for the current year.

In other Bausch Health Companies news, CFO Sam Eldessouky sold 17,000 shares of the stock in a transaction on Friday, June 11th. The stock was sold at an average price of $31.68, for a total value of $538,560.00. Following the completion of the sale, the chief financial officer now owns 116,857 shares in the company, valued at approximately $3,702,029.76. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Amy B. Wechsler sold 11,037 shares of the firm’s stock in a transaction dated Wednesday, May 26th. The shares were sold at an average price of $31.79, for a total value of $350,866.23. Following the transaction, the director now owns 98,325 shares of the company’s stock, valued at approximately $3,125,751.75. The disclosure for this sale can be found here. Insiders sold a total of 149,235 shares of company stock valued at $4,747,159 in the last quarter. 13.75% of the stock is currently owned by company insiders.

Bausch Health Companies Profile

Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products.

Featured Story: Why does a company issue an IPO?

Want to see what other hedge funds are holding BHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bausch Health Companies Inc. (NYSE:BHC).

Institutional Ownership by Quarter for Bausch Health Companies (NYSE:BHC)

Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.